Altis Labs Raises US$25 Million Series A Co-Led by OrbiMed and Qiming Venture Partners USA to Accelerate Clinical Development with
Altis Labs has secured $25 million in Series A funding to advance its clinical development platform, which utilizes real-world data to improve patient outcomes. While the company focuses on clinical trial acceleration, its integration of health data and patient-centric technology aligns with the broader trend of venture capital investment in health-tech solutions that address chronic disease management and patient well-being.
HNH Insight
While not exclusively a 'Food is Medicine' startup, this funding event highlights the current venture capital appetite for health-tech platforms that leverage data to improve clinical outcomes, a sector that frequently overlaps with the 'Food is Medicine' ecosystem's focus on data-driven health interventions.
Exchange Discussion
Join the expert conversation on this article in the HN&H Intelligence Exchange. Professional discussion only — cite your sources.
No comments yet.
